PANCREATIC DUCTAL ADENOCARCINOMA

This early-phase study tested whether adding a new drug called NP137 to standard chemotherapy (mFOLFIRINOX) is safe for people with locally advanced pancreatic cancer that cannot be removed by surgery. 43 adults aged 18-79 took part. The main goal was to track side effects, while…

This study tested two standard chemotherapy combinations in 150 people with advanced pancreatic cancer that had spread. The goal was to see which worked better and to use lab tests on tumors to predict responses. Participants received either modified FOLFIRINOX or gemcitabine plu…

This study tested a combination of three chemotherapy drugs (paclitaxel protein bound, gemcitabine, and cisplatin) in 34 people with metastatic pancreatic cancer that had not been treated before. The goal was to see how well the drugs shrank tumors and helped people live longer. …

This early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had minimal residual disease (small amounts of cancer left after standard treatment). The goal was to see if t…

This study tested a combination of three chemotherapy drugs (nab-paclitaxel, cisplatin, and gemcitabine) in 42 people with metastatic pancreatic cancer that had not been treated before. The goal was to see if this mix could help patients live longer and control the disease. The t…

This study looked at 546 people who had surgery for pancreatic cancer. It tested whether adding a targeted drug (erlotinib) or radiation therapy to standard chemotherapy could help them live longer. The goal was to see if these extra treatments could kill any remaining cancer cel…

This study tested a combination of three drugs (nivolumab, BMS-813160, and GVAX) in 22 people with locally advanced pancreatic cancer who had already received chemotherapy and radiation. The goal was to see if the treatment was safe and could help the immune system better attack …

This study tested a new drug called MK-1200 in 13 people with advanced solid tumors, including stomach, esophageal, bile duct, and pancreatic cancers. The goal was to find safe doses and see if the drug could shrink tumors. The study is complete, but results are not yet available…

This study tested a new treatment plan for people with advanced pancreatic cancer that has spread. It combined chemotherapy with drugs that change how genes work and boost the immune system. The goal was to see if this approach is safe and can help control the disease. 75 patient…

This study tested whether adding two immunotherapy drugs (pembrolizumab and defactinib) to standard chemotherapy before and after surgery could help the body fight pancreatic cancer better. It involved 28 people with early-stage, removable pancreatic cancer. The goal was to see i…

This study tested a new drug called onvansertib combined with standard chemotherapy for people with advanced pancreatic cancer that had spread. The goal was to see if the combination could shrink tumors or control the disease. 41 adults who had already tried one type of chemother…

This study tested a new imaging agent (64Cu-DOTA-ECL1i) for PET scans to detect a specific marker (CCR2) on pancreatic cancer cells. The goal was to see if the scan could help doctors choose the right treatment and monitor how well it works. 69 adults with pancreatic cancer parti…

This study tested a new type of PET scan called [18F]FAPI-74 in 109 people with gastrointestinal cancers, including liver, bile duct, stomach, pancreas, and colorectal cancers. The scan looks for a protein called FAP that is often found on cancer cells. Researchers compared the s…